Celldex Therapeutics, Inc. (CLDX - Free Report) presented results from a phase II study evaluating the combination of its pipeline candidates CDX-301 and CDX-1401 in patients with malignant melanoma at the annual meeting of the American Society of Clinical Oncology. The study was conducted by the Cancer Immunotherapy Trials Network under a Cooperative Research and Development Agreement between Celldex and the Cancer Therapy Evaluation Program of the National Cancer Institute.
Results from the study showed that the combination of CDX-1401 and CDX-301 generated significant NY-ESO-1 specific T cell responses in patients with melanoma. On the safety front, both combination regimens were found to be well tolerated with no drug-related adverse events being reported that required discontinuation of treatment.
Given the encouraging phase II study results, Celldex announced the initiation of a targeted study in patients with NY-ESO-1 positive disease to evaluate whether these enhanced immune responses can lead to improved clinical outcomes.
Currently, prescribed treatments for melanoma include drugs like Opdivo and Yervoy.
Apart from CDX-301 and CDX-1401, other candidates in Celldex’s pipeline include glembatumumab vedotin (phase II studies for triple negative breast cancer and metastatic melanoma), varlilumab (phase I/II, several combination studies across multiple types of cancer) and CDX-014 (phase I, renal cell carcinoma).
Celldex is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Retrophin, Inc. – both sporting a Zacks Rank #1 (Strong Buy) and Acorda Therapeutics, Inc. – carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Celldex Therapeutics, Inc. (CLDX - Free Report) presented results from a phase II study evaluating the combination of its pipeline candidates CDX-301 and CDX-1401 in patients with malignant melanoma at the annual meeting of the American Society of Clinical Oncology. The study was conducted by the Cancer Immunotherapy Trials Network under a Cooperative Research and Development Agreement between Celldex and the Cancer Therapy Evaluation Program of the National Cancer Institute.
Results from the study showed that the combination of CDX-1401 and CDX-301 generated significant NY-ESO-1 specific T cell responses in patients with melanoma. On the safety front, both combination regimens were found to be well tolerated with no drug-related adverse events being reported that required discontinuation of treatment.
Given the encouraging phase II study results, Celldex announced the initiation of a targeted study in patients with NY-ESO-1 positive disease to evaluate whether these enhanced immune responses can lead to improved clinical outcomes.
Currently, prescribed treatments for melanoma include drugs like Opdivo and Yervoy.
Apart from CDX-301 and CDX-1401, other candidates in Celldex’s pipeline include glembatumumab vedotin (phase II studies for triple negative breast cancer and metastatic melanoma), varlilumab (phase I/II, several combination studies across multiple types of cancer) and CDX-014 (phase I, renal cell carcinoma).
Celldex is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Retrophin, Inc. – both sporting a Zacks Rank #1 (Strong Buy) and Acorda Therapeutics, Inc. – carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CLDX - FREE
Get the latest research report on ANIP - FREE